Search
for

    Learn

    3 / 3 results

      learn Baricitinib

      JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

      learn Tofacitinib

      a JAK inhibitor for alopecia areata and other autoimmune conditions

    Research

    5 / 1000+ results

    Community Join

    5 / 47 results

      community So we’re just ok with taking a research chemical now?

      in Treatment  179 upvotes 3 years ago
      The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

      community What else is good. Besides the big 3.

      in Chat  34 upvotes 2 months ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community The Worst Hair Loss Condition You (MAY) have: LPP

      in Research/Science  43 upvotes 3 months ago
      Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

      community DUPA - 20 YO - Non responder to everything

      in Finasteride/Dutasteride  13 upvotes 3 months ago
      A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.